CN116983320A - Nucleic acid medicine for treating skin fibrosis and preparation method and application thereof - Google Patents
Nucleic acid medicine for treating skin fibrosis and preparation method and application thereof Download PDFInfo
- Publication number
- CN116983320A CN116983320A CN202311158848.2A CN202311158848A CN116983320A CN 116983320 A CN116983320 A CN 116983320A CN 202311158848 A CN202311158848 A CN 202311158848A CN 116983320 A CN116983320 A CN 116983320A
- Authority
- CN
- China
- Prior art keywords
- birds
- nucleic acid
- tfna
- skin fibrosis
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 32
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 32
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 32
- 206010050207 Skin fibrosis Diseases 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 239000002086 nanomaterial Substances 0.000 claims abstract description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 7
- 230000000295 complement effect Effects 0.000 claims abstract description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 14
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 14
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 230000006907 apoptotic process Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000463 material Substances 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 230000030833 cell death Effects 0.000 abstract 1
- 230000001603 reducing effect Effects 0.000 abstract 1
- LMRJHNFECNKDKH-UHFFFAOYSA-N 4-(trifluoromethyl)nicotinic acid Chemical compound OC(=O)C1=CN=CC=C1C(F)(F)F LMRJHNFECNKDKH-UHFFFAOYSA-N 0.000 description 59
- 210000004027 cell Anatomy 0.000 description 38
- 210000003491 skin Anatomy 0.000 description 30
- 230000014509 gene expression Effects 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 20
- 206010016654 Fibrosis Diseases 0.000 description 19
- 230000004761 fibrosis Effects 0.000 description 19
- 230000037361 pathway Effects 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 17
- 238000010166 immunofluorescence Methods 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 238000010586 diagram Methods 0.000 description 13
- 238000012764 semi-quantitative analysis Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 238000000246 agarose gel electrophoresis Methods 0.000 description 12
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 108091070501 miRNA Proteins 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 102100035904 Caspase-1 Human genes 0.000 description 9
- 108090000426 Caspase-1 Proteins 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 239000002679 microRNA Substances 0.000 description 9
- 108010006654 Bleomycin Proteins 0.000 description 8
- 102000016359 Fibronectins Human genes 0.000 description 8
- 108010067306 Fibronectins Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229960001561 bleomycin Drugs 0.000 description 8
- 238000012512 characterization method Methods 0.000 description 8
- 229940090044 injection Drugs 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 7
- 230000003176 fibrotic effect Effects 0.000 description 7
- JGBUYEVOKHLFID-UHFFFAOYSA-N gelred Chemical compound [I-].[I-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCCCC(=O)NCCCOCCOCCOCCCNC(=O)CCCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 JGBUYEVOKHLFID-UHFFFAOYSA-N 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 102000012422 Collagen Type I Human genes 0.000 description 6
- 108010022452 Collagen Type I Proteins 0.000 description 6
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 6
- 206010033675 panniculitis Diseases 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000004304 subcutaneous tissue Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- 229960002591 hydroxyproline Drugs 0.000 description 4
- 230000002055 immunohistochemical effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 4
- 102000000905 Cadherin Human genes 0.000 description 3
- 108050007957 Cadherin Proteins 0.000 description 3
- 102100037388 Gasdermin-D Human genes 0.000 description 3
- 101001026262 Homo sapiens Gasdermin-D Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000024798 heartburn Diseases 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 208000024981 pyrosis Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 102000003810 Interleukin-18 Human genes 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 208000002260 Keloid Diseases 0.000 description 2
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 2
- 102000057208 Smad2 Human genes 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000001117 keloid Anatomy 0.000 description 2
- 210000000651 myofibroblast Anatomy 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- SFAYBQDGCKZKMH-UHFFFAOYSA-N BNCC Chemical compound BNCC SFAYBQDGCKZKMH-UHFFFAOYSA-N 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 235000013939 Malva Nutrition 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010020147 Protein Corona Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 102000007374 Smad Proteins Human genes 0.000 description 1
- 108010007945 Smad Proteins Proteins 0.000 description 1
- 101150057615 Syn gene Proteins 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003367 anti-collagen effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229940040609 bleomycin injection Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 101150031548 ecm gene Proteins 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 108700016226 indium-bleomycin Proteins 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940080182 methotrexate injection Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940072113 onion extract Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000008491 skin homeostasis Effects 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940125379 topical corticosteroid Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a nucleic acid medicine for treating skin fibrosis, a preparation method and application thereof, and belongs to the field of nucleic acid molecule medicines. The invention firstly provides a tetrahedral framework nanomaterial for treating skin fibrosis, which is prepared by base complementary pairing of nucleotide sequences shown in SEQ ID NO. 5-8. The tetrahedral framework nanomaterial can be used for preparing nucleic acid medicines for treating skin fibrosis. The tetrahedron nanometer material of the invention has the functions of resisting cell death and inflammation, reducing skin fibrosis, and being used in preparing nucleic acid medicine for treating skin fibrosis.
Description
Technical Field
The invention belongs to the field of nucleic acid molecule medicaments, and in particular relates to a nucleic acid medicament for treating skin fibrosis, a preparation method and application thereof.
Background
Skin is the largest organ of the human body and plays a vital role as the first line of defense against various endogenous and exogenous infectious factors and injuries. Adverse events affect skin homeostasis, making the skin susceptible to a variety of stimuli and toxins. When the intensity or duration of a skin injury exceeds the capacity of tissue repair, skin fibrosis caused by a disregulation of the tissue repair response begins to dominate the repair process. The heterogeneity of skin tissue repair reactions can lead to scar formation, which is the result of pathologically connective skin tissue repair, which can be observed in hypertrophic scars and keloids, while scleroderma or scleroderma occurs in a limited or diffuse type of systemic sclerosis.
Skin fibrosis not only affects aesthetics, but also causes the skin to lose elasticity and activity, and many uncomfortable symptoms appear, seriously affecting work and life. Current methods of treatment of hypertrophic scars and keloids, such as topical corticosteroid injection, surgical revision, cryotherapy, radiation therapy, and even the use of silica gel containing onion extract, cannot fundamentally treat, are prone to recurrence and must be repeated. For scleroderma, there is no generally accepted treatment, steroid hormone, methotrexate injection can be used, but the side effects are large. It can be seen that the existing treatment methods can not achieve ideal curative effects.
In recent years, various novel nucleic acid materials, such as nano-sized material tetrahedral framework nucleic acids (tFNAs), have been developed and widely used in various fields. tFNAs can act as anti-inflammatory and antioxidant agents to promote wound healing in the skin. Previous studies have shown that tFNA can carry mirnas to deliver mirnas into cells or tissues that perform specific functions without a vector. In view of its excellent biosafety and biocompatibility, the tFNA structure is further optimized, and miRNA is further optimized from a cohesive end linkage as part of a tetrahedral structure, improving the delivery efficiency of miRNA. The material is expected to be used for treating fibrotic diseases, in particular pulmonary fibrotic diseases.
Most of the existing methods for carrying miRNA on tetrahedrons need to adhere the sticky end to the vertex or the side arm of the tetrahedron frame, which causes the problems of overlarge material diameter, poor stability, low medicine carrying efficiency and the like.
Further research is needed on how to improve the therapeutic effect of tetrahedra on skin diseases.
Disclosure of Invention
The invention aims to provide a nucleic acid medicine for treating skin fibrosis, and a preparation method and application thereof.
The invention provides a tetrahedral framework nano material for treating skin fibrosis, which is prepared by base complementary pairing of nucleotide sequences shown in SEQ ID NO. 5-8.
Further, the molar ratio of the nucleotide sequence shown in SEQ ID NO. 5-7 to the nucleotide sequence shown in SEQ ID NO.8 is (1-5): 3-15.
Further, the molar ratio of the nucleotide sequence shown in SEQ ID NO. 5-7 to the nucleotide sequence shown in SEQ ID NO.8 is 1:1:1:3.
The invention also provides a preparation method of the tetrahedral framework nano material, which comprises the following steps:
mixing the nucleotide sequences shown in SEQ ID No. 5-8 in a solvent, maintaining the temperature at 90-95 ℃ for 10-20 minutes, and rapidly cooling to 4-10 ℃ and maintaining the temperature for more than 20 minutes to obtain the nucleotide sequence.
Further, the solvent is a TM buffer.
Further, the TM buffer is prepared from 10mM Tris-HCl and 50mM MgCl 2 Dissolving in water, and adjusting pH to 8.0.
The invention also provides application of the tetrahedral framework nanomaterial in preparing nucleic acid medicines for treating skin fibrosis.
Further, the nucleic acid drug is an anti-cell apoptosis drug.
Further, the nucleic acid drug is an anti-inflammatory drug.
Further, the nucleic acid agent is an agent that inhibits the TGF-beta/Smad pathway.
Compared with the prior art, the invention has the beneficial effects that:
the invention provides a novel tetrahedral nano material, which is loaded with miRNA-27a molecules, can resist cell apoptosis and anti-inflammatory activity, can reduce skin fibrosis, can be used for preparing nucleic acid medicines for treating skin fibrosis, and has wide application prospect.
It should be apparent that, in light of the foregoing, various modifications, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
The above-described aspects of the present invention will be described in further detail below with reference to specific embodiments in the form of examples. It should not be understood that the scope of the above subject matter of the present invention is limited to the following examples only. All techniques implemented based on the above description of the invention are within the scope of the invention.
Drawings
FIG. 1 shows the results of preparation and characterization of BiRDS and tFNA: a is a synthetic schematic diagram of BiRDS; b is an agarose gel electrophoresis result graph of BiRDS and tFNA and a Cy5 and Gelred fluorescence intensity characterization result ImageJ semi-quantitative analysis graph; c is a size distribution and zeta potential result graph of BiRDS and tFNA; d is an AFM morphology analysis result graph of BiRDS and tFNA; e is an agarose gel electrophoresis result diagram of BiRDS incubated for 2 hours at the temperature of 0-10% serum 37 ℃ and an image J semi-quantitative analysis diagram of Cy5 and Gelred fluorescence intensity characterization results; f is an agarose gel electrophoresis result diagram of BiRDS incubated for 0-24 hours at the temperature of 1% serum 37 ℃ and an image J semi-quantitative analysis diagram of Cy5 and Gelred fluorescence intensity characterization result; g is an agarose gel electrophoresis result graph of BiRDS incubated for 0-7 days at a serum-free room temperature of 25 ℃, and a Cy5 and Gelred fluorescence intensity characterization result imageJ semi-quantitative analysis graph; h is a schematic diagram of BiRDS entering cells and being decomposed by enzyme to release miRNA.
FIG. 2 shows the results of in vitro experiments of BiRDS and tFNA cell entry and fibrosis inhibition: a is a cell entering schematic diagram of BiRDS and tFNA; b is semi-quantitative analysis of a cell-entering schematic Cy5 of BiRDS and tFNA at different time points of culture; c is the experimental result of the activity CCK8 of the HaCaT cells of tFNA and BiRDS; d is an immunofluorescence result graph of the expression influence of miRNA, tFNA and BiRDS on alpha SMA in a HaCaT cell fibrosis model established by TGF-beta; e is a western blot experiment (WB) result diagram of the expression influence of miRNA, tFNA and BiRDS on alpha SMA and type I collagen in a HaCaT cell fibrosis model established by TGF-beta; f is an imageJ semi-quantitative analysis chart of alpha SMA expression in D; g is an immunofluorescence result graph of the effect of miRNA, tFNA and BiRDS on the expression of E-cadherein in a HaCaT cell fibrosis model established by TGF-beta; h is an ImageJ semi-quantitative analysis chart expressed by E-cadherin in G; i is an ImageJ semi-quantitative analysis chart of alpha SMA expression in E; J. k is an immunofluorescence result graph and an ImageJ semi-quantitative analysis graph of the effect of miRNA, tFNA and BiRDS on the expression of type I collagen in a HaCaT cell fibrosis model established by TGF-beta.
FIG. 3 is a chart of BiRDS inhibition smad2/3 pathway and focal death pathway: a is the WB result of Fibronectin and smad2/3 analysis of protein expression level; B. c is the IF image and 3D heatmap of fibronectin and smad 2/3; D. e is the semi-quantitative result analysis of WB and IF experiments in A-C; f is a schematic diagram of the influence of BiRDS on different molecules and cell behaviors in the focusing death path; g is BiRDS and tFNA inhibiting protein WB result diagram related to the scorching pathway; H. i is the IF image and 3D heat map of caspase-1 and IL-1β; J-N is a semi-quantitative analysis chart of the expression of the protein related to the apoptosis in the WB and IF experiments in sequence.
FIG. 4 is the experimental results of BiRDS inhibiting skin fibrosis in vivo: a is an in-vivo experimental scheme diagram, comprising the establishment of a fibrosis model, the injection of bleomycin, the detection of molecular biology and the data analysis; b is Masson staining of skin tissue on day 21; c is skin thickness and data analysis chart at days 0, 7, 14 and 21; d is a skin hydroxyproline content analysis chart of the back of the mice in the experiment group on the 21 st day; e is a skin tissue HE staining chart, and the enlarged solid and dotted boxes represent an epithelial structure and a subcutaneous tissue structure respectively; F. g is a fluorescence signal intensity profile detected within 120 minutes of injection of the miR-27a mimetic, biRDS and tFNA.
FIG. 5 shows the results of BiRDS inhibiting bleomycin induced EMT and smad pathways: a is TGF-beta, activates EMT and smad2/3 pathway in animal tissue, and can be reversed by BiRDS; B. c is an image of TGF-beta and alpha SMA expression from an Immunohistochemical (IHC) staining experiment performed on skin tissue; d is a dual fluorescent staining pattern of smad and fibronectin expression levels; e is the index gray value analysis chart in FIG. 5B, F is the index gray value analysis chart in FIG. 5C, and G is the index immunofluorescence intensity gray value analysis chart in FIG. 5D.
Fig. 6 is a diagram of the BiRDS inhibiting the focal death pathway and inflammation in vivo: A. d is the IF result of caspase-1 cleaved in bleomycin group hair follicles; B. e is IHC staining image of IL-1 beta; C. f is an IHC staining image and analysis of bleomycin induced up-regulation of the typical inflammatory cytokine tnfα in skin tissue.
Detailed Description
The materials and equipment used in the embodiments of the present invention are all known products and are obtained by purchasing commercially available products.
In the invention, miRNA-27a can be abbreviated as miR27a.
Example 1 preparation of DNA tetrahedron framework nanonucleic acid drug carrying miRNA27a
1. Preparation of BiRDS and tFNA
The nucleotide sequences in the single DNA/RNA strand (ssDNA/ssRNA) are shown in Table 1. All ssDNA/ssRNA was synthesized by Sangon co., ltd., ltd. (Shanghai, china).
Preparation of tFNA: 4 ssDNA (S1-4-T, 1. Mu.M) at equimolar concentration were added to TM buffer (10 mM Tris-HCl and 50mM MgCl) 2 Dissolved in water and pH adjusted to 8.0 with hydrochloric acid), then the whole solution was heated to 95 ℃ for 10 minutes and immediately cooled in a thermal cycler at 4 ℃ for 20 minutes to complete the denaturation and assembly process to give tFNA.
Preparation of BiRDS: three single stranded DNA/RNA (S1-3-BiRDS, 1. Mu.M) and miRNA-27a (3. Mu.M) were added to TM buffer (10 mM Tris-HCl and 50mM MgCl) at equimolar concentrations 2 Dissolve in water and adjust pH to 8.0 with hydrochloric acid), then heat the entire solution to 95 ℃ for 10 minutes and immediately cool in a thermal cycler at 4 ℃ for 20 minutes to complete the denaturation and assembly process, resulting in a BiRDS tetrahedral structure. FIG. 1A is a schematic diagram of the synthesis of BiRDS.
TABLE 1 nucleotide sequences of the single DNA/RNA strand
2. Structural characterization of BiRDS and tFNA
To confirm successful synthesis of BiRDS and tFNA, nucleic acids were isolated using GelRed-stained 2% Agarose Gel Electrophoresis (AGE) and running at 120V for 30 minutes in an electrophoresis apparatus (Bio-Rad, usa). To verify the nanostructure of BiRDS and tFNA, their morphology was observed using an Atomic Force Microscope (AFM) (kyoto island in japan). The dimensions and zeta potential of the BiRDS and tFNA were measured using the Zetasizer Nano ZS system (england malva). And (3) grafting Cy5 (Cy 5-S1-T) on the S1-T chain of the tFNA during agarose gel electrophoresis detection, then preparing the tFNA (Cy 5-tFNA) according to the method, or grafting Cy5 (Cy 5-miRNA-27 a) on miRNA-27a, and then preparing the BiRDS (Cy 5-BiRDS) according to the method.
FIG. 1B is a graph of the agarose gel electrophoresis results of BiRDS and tFNA and a graph of the semi-quantitative analysis of Cy5 and Gelred fluorescence intensity characterization results of ImageJ, and the graph of the tFNA agarose gel electrophoresis results, the graph of the BiRDS agarose gel electrophoresis results, and the Cy5 and Gelred fluorescence intensity characterization results are sequentially shown from left to right. Agarose gel electrophoresis (FIG. 1B) confirmed the successful synthesis of tFNA and BiRDS, revealing the molecular weights of the intermediate, tFNA and BiRDS, about 30 to 180bp. Notably, single-stranded DNACy5 showed a weaker fluorescence intensity than the single-stranded DNA supported on the frame at the same electrophoresis time, indicating better stability of the single-stranded DNA (in red dashed box) with the single-stranded DNA exposed on the frame. In the chart of the result of BiRDS agarose gel electrophoresis of FIG. 1B, r is the structure formed by the synthesis of miRNA-27a, S123+r, S123+2r and S123+3r respectively represent S1-BiRDS, S2-BiRDS and S3-BiRDS chains with equimolar concentration and a miRNA-27a mixed system with 1-time, 2-time or 3-time molar concentration. The single-stranded miR27a was attached to the tetrahedral framework nucleic acid in proportion and showed the same trend of fluorescent growth.
AFM morphology analysis of tFNA and BiRDS (fig. 1D) revealed triangular nanoscale particles with a diameter of 10nm, consistent with the size distribution determined by dynamic light scattering (fig. 1C). Both tFNA and BiRDS were negatively charged and the average zeta potential was-7.70 mV and-8.72 mV, respectively. This property favors the rejection of ROS and the reaction with certain functional proteins, which is also the basic principle of electrophoretic separation.
The beneficial effects of the present invention are demonstrated by specific test examples below.
Serum stability of test example 1, biRDS and tFNA
1. Experimental method
To verify stability and storage capacity of tFNA and BiRDS in serum, the Cy 5-linked BiRDS prepared according to example 1 was incubated with serum of different concentrations and tested for serum stability under 3 reaction conditions: (1) Incubating in 0-10% strength fetal bovine serum (FBS, corning company, NY) at 37 ℃ for 2 hours, (2) incubating for 0-24 hours at 37 ℃ in 1% fetal bovine serum; (3) Incubation is carried out for 0-7d under the condition of 25 ℃ in 0% fetal bovine serum. The solvent for adjusting the concentration of the fetal bovine serum is PBS buffer.
After incubation, the samples were used in the presence of 5mM Mg 2+ The final product was detected by performing a PAGE experiment in 0.5 xTAE buffer. In order to ensure stability of the final product during the detection, the present invention cools the liquid medium in advance and places it in an ice bath. The gel was visualized using a gel and blot imaging system (bamboole Syngene, india).
2. Experimental results
The present invention incubates BiRDS with 0-10% FBS for 2 hours at 37℃to simulate the in vivo environment and ideal growth conditions of cells. The fluorescence signal of Cy5 detected by PAGE indicated that as FBS concentration was further increased to 10%, the bisds retained the non-serogroup content of 70%, indicating that bisds had good stability in vivo for 2 hours. FIG. 1F illustrates that BiRDS has good stability over 24 hours of incubation in 1% FBS, and that BiRDS was incubated in 1% FBS to simulate the culture environment, and after 24 hours, the fluorescence intensity of Cy5 was maintained at 85% at 0 hours. This ensures that the BiRDS remains in its original form for 24 hours, thereby providing a reliable measure of the number of particles entering the cell, ensuring that the nucleic acid drug is able to enter the cell effectively over a period of time. The storage conditions of the biologics are extremely stringent to maintain their efficacy, which conditions result in high health costs for cryopreservation during cold chain logistics, and FIG. 1G shows that BiRDS exhibits extremely high stability at room temperature (25 ℃) for at least 7 days, and maintains at least 75% of the viability of miR-27a, which is easy to store, facilitating its use in complex environments and in Schottky regions.
Test example 2, cell uptake and cell treatment of BiRDS and tFNA
1. Experimental method
HaCaT cells (BNCC, henan, china) were cultured in RPMI-1640 medium containing 10% FBS and 1% (v/w) penicillin/streptomycin (Hyclone, USA) at 37℃and 5% CO 2 Is cultured in a humid incubation environment. FBS in the flask was gradually reduced to 1% for 3 hours prior to incubation of the cells with the nucleic acid drug to reduce protein corona formation and prepare for the next procedure.
For cell uptake experiments, haCaT cells seeded in confocal dishes were incubated in medium containing different concentrations of nucleic acid drug (Cy 5-tFNA 250nM, cy5-BiRDS250nM, cy 5-S1-T750 nM, cy5-miRNA-27a 750 nM). After 6-12h incubation, samples were fixed with 4% paraformaldehyde for 30min, and nuclei and cytoplasm were labeled with DAPI and Fluorescein Isothiocyanate (FITC), respectively. Sections were washed three times with PBS for 5 minutes between adjacent steps. Finally, an image was captured using a confocal laser microscope (FV 3000, olympus japan). Cy5-tFNA, cy5-BiRDS, cy5-S1-T and Cy5-miRNA-27a were prepared as described in example 1.
2. Experimental results
The interaction between BiRDS and HaCaT cells is critical for inhibiting fibrosis. BiRDS enters the complex intracellular environment through a small-cell protein mediated endocytic pathway and is targeted by RNase H recognizing the DNA and RNA hybridization region (containing purple hydrogen bonds). The three-dimensional structure of the BiRDS is then converted into a two-dimensional planar structure. In addition, miRNA-27a molecules are released into the cytoplasm to perform different functions. To compare the cellular uptake efficiency of BiRDS with tFNA and related single strands, the present invention uses immunofluorescence to detect the uptake of miRNA-27a by inserting 250nM fluorescent Cy5-tFNA, cy5-BiRDS and fluorescent single strands with the same concentration of Cy 5. As shown in fig. 2A and 2B, biRDS localizes in the cytoplasm in the same manner and exhibits almost the same uptake efficiency as tFNAs. After 12 hours incubation with HaCaT cells, the fluorescence intensity of Cy5 in both the BiRDS and tFNA groups remained at the same level and showed no statistical difference, although the time of BiRDS entry into the cells appeared to be slightly later than tFNA. Both exhibit higher cell permeability. In FIG. 2B, S is Cy5-S1-T, T is Cy5-tFNA, m is Cy5-miRNA-27a, and Bi is Cy5-BiRDS.
Test example 3 cell viability measurements of BiRDS and tFNA
1. Experimental method
To examine the effect of nucleic acid drugs on HaCaT cells, a cell count kit-8 (CCK 8) assay was performed. Different concentrations (31.3, 62.5, 125, 250 and 500 nM) of tFNas and BiRDS were incubated with cells in 96-well plates for 24 hours, then 10. Mu.L of CCK-8 solution was added to the wells and measured at an absorbance of 450 nM. tFNAs and BiRDS were prepared as described in example 1.
2. Experimental results
The invention uses CCK8 experiments to detect cell proliferation and viability. HaCaT cells showed increased proliferation capacity after incubation with tFNA and BiRDS at gradient concentrations of 31.3nM to 500nM (fig. 2C), indicating the non-toxicity of both nucleic acid drugs. In addition, tFNA and BiRDS showed the strongest ability to enhance cell viability at concentrations of 250nM and 125nM, respectively. Thus, the present invention selects these concentrations as the optimal concentrations for subsequent experiments.
Test example 4 Immunofluorescence (IF) assessment of BiRDS and tFNA
1. Experimental method
After HaCaT cells were seeded on confocal dishes and the density was close to 60%, related modeling and treatments were performed:
in addition to the control group (normal HaCaT cells, ctrl), the other four groups were treated with 5ng/mL TGF- β (transforming growth factor β) (MedChemExpress, monmouth Junction, NJ) for 24 hours to model skin fibrosis, and 3 groups were incubated with nucleic acid drug (miRNA-27a 375nM,tFNA250 nM,BiRDS125nM) added simultaneously with TGF- β, respectively.
The harvested samples were fixed with 4% paraformaldehyde for 30min, then with 0.5% Triton X-100 for 10 min, and with 5% sheep serum for 1 hr. Various concentrations of diluted primary antibodies were incubated overnight at 4 ℃ (α -smooth muscle actin (α -SMA), 1:500; fibronectin, 1:300; collagen I,1:300; e-cadherin, 1:500; smad2/3,1:300; cleaved caspase-1, 1:250; il-1β, 1:150), and then the corresponding fluorescent secondary antibodies FITC and DAPI (martial Servicebio, china) were incubated with the samples for 1 hour, 30 minutes and 10 minutes, respectively. Similarly, confocal laser microscopy was used to capture fluorescent signals, while fluorescence intensity measurements of one protein selected the same parameters.
2. Experimental results
Tissues contribute to resilience and strength by maintaining extracellular matrix (ECM) secreted by mesenchymal cells and other matrix components. The over-expressed TGF- β will promote the development of epithelial cells to fibroblasts, known as epithelial-mesenchymal transition (EMT). The invention herein uses transforming growth factor-beta as an actuator to model fibrosis in vitro. After 24 hours of addition of 5 ng/mLTGF-beta to the medium, the mesenchymal marker alpha-SMA was upregulated 3.2-fold. However, it was reversed when exposed to 250nM tFNA and 125nM BiRDS. Compared to the tFNA group, the expression level of α -SMA was lower, and the BiRDS restored the extent of EMT to almost the same level as the control group (fig. 2D-2F).
E (epithelial) -cadherin, known as a "cell adhesion" glycoprotein, is a single transmembrane protein responsible for intercellular cross-talk and maintains the polarity and integrity of epithelial cells. E-cadherin silencing has long been recognized as a key driver affecting epithelial cell separation from one another and leading to a dramatic loss of cell polarity. The factor may be regulated in content or location by various fibrotic cytokines, including TGF- β. In the IF test, the present invention observed that after 5 ng/mLTGF-beta treatment, the fluorescent signal of E-cadherin became weaker and blurry, indicating that its downregulation and dislocation was due to EMT. These changes were reversed after tFNA and BiRDS treatment. Proteins returned to the membrane and showed a clearer, slightly lighter fluorescent signal than the control group, which helped to maintain the polarity and stability of HaCaT cells (fig. 2G and 2H).
BiRDS reduces expression of matrix proteins and inhibits the smad2/3 pathway. In chronic fibrotic disease, TGF- β favors mesenchymal transformation of epithelial cells and promotes transformation into myofibroblast-like cells. In the late stages, excess extracellular matrix (ECM), including type I collagen, fibronectin, elastin, and proteoglycans, increases due to increased synthesis and decreased degradation in fibroblasts. In the skin fibrosis model of the present invention, 5ng/mL TGF-beta promoted expression of type I collagen and fibronectin in HaCaT cells at 1.6 and 4.3 fold, respectively (FIGS. 3B and 3D). Although 250nM tFNA mainly reversed pathogenic synthesis of both proteins and the same concentration of miR-27a molecules exerted their effect by entering the cells, as previously reported, biRDS as a more efficient version of tFNA and a protective agent for delivery of miR-27a achieved excellent inhibition at low concentrations of 125nM (FIGS. 2J and 2K).
TGF-beta is closely related to fibrosis and is the basis for regulating ECM gene expression. Its downstream molecules, including Smad2/3, act as the basis and key mediators in fibrosis occurrence, becoming an effective target for anti-fibrotic therapy for preventing tissue fibrosis. Based on WB and IF results, smad2/3 was down-regulated when HaCaT cells were treated with tFNAs and BiRDS simultaneously (fig. 3A, 3C and 3E). Although tFNAs showed a powerful therapeutic effect, biRDS further enhanced the inhibition response and optimized the results at nearly the same level as the control group. These results indicate that BiRDS is a stronger nanoscale therapeutic that inhibits the TGF- β/Smad pathway and treats skin fibrotic diseases.
Furthermore, tFNA showed potent inhibition of the focal pathway (fig. 3H and 3I), but BiRDS inhibited the downstream pathway protein more strongly due to interaction with miRNA-27 a.
Test example 5 Western Blot (WB) assay of BiRDS and tFNA
1. Experimental method
After treatment according to the method described in test example 4, cells were harvested using a whole protein extraction kit (KeyGen biotechco., ltd., south kyo, china) to obtain total protein measurements. Target proteins were separated using 10-12% Sodium Dodecyl Sulfate (SDS) -PAGE. Proteins of a specific molecular weight were transferred to PVDF membranes and immediately blocked with 5% Bovine Serum Albumin (BSA) for 1 hour. After incubation overnight with primary antibodies [ anti- α -SMA (1:1000), anti-E-cadherin (1:10000), anti-collagen I (1:1000), anti-fibronectin (1:1000), anti-TNF- α (1:800), anti-NLRP 3 (1:1000), anti-lytic caspase-1 (1:1000), anti-GSDMD (1:1000), anti-IL-18 (1:1000), anti-IL-1β (1:1000) ] at 4 ℃, PVDF membranes were incubated with the appropriate secondary antibodies (1:3000) for 1 hour. Exposure signals were acquired from the gel and blot imaging system for subsequent semi-quantitative analysis in ImageJ.
2. Experimental results
The results show that: both alpha-SMA and type I collagen increased after 5ng/mL TGF-beta treatment, and BiRDS and tFNA inhibited the decrease in both levels (FIG. 2I). TFNA and BiRDS inhibited fibronectin and Smad2/3 to different degrees, with the same trend as the results in test example 4. The classical focal death pathway recruits NLRP3 and forms inflammatory corpuscles with caspase-1. Activated caspase-1 promotes cleavage and pore formation of GSDMD, thereby promoting exudation of mature IL-18 and IL-1β (FIG. 3F). After miR27a treatment, NLRP3 expression was down-regulated compared to TGF- β group (fig. 3G and 3J). The unique structure of BiRDS can be used as a delivery carrier for transferring miRNA-27a into cells, and the stability of a single chain can be maintained even if the miRNA with the same concentration is added. In the BiRDS group, almost all of the pyro-proteins were inhibited to the level of the control group. In contrast, GSDMD, caspase-1, IL-18 and IL-1β reached lower levels in WB (FIGS. 3J-3N), indicating that tFNA and BiRDS are anti-scorch drugs with high application potential.
Test example 6, animal model building and grouping
1. Experimental method
All animal experiments were performed according to the animal ethics committee of the university of Sichuan Hua Xi oral medical college. 60 BALB/c mice (6-8 weeks old, 18-22 g) were purchased from Gemphamatech Inc. (Nanj, china) and kept in a 12/12h light/dark cycle. They are used as animal models of fibrosis, and the specific model construction method is as follows: after 7 days of adaptive feeding, mice were injected with 0.1mL of 0.5mg/mL bleomycin hydrochloride (B) on specific areas of the dorsal skin for 3 weeks (once every two days over a period of 3 weeks). Over the next 3 weeks, the mice were divided into six groups: control group, B, B+mi R27a, B+T, B+125nM BiRDS and B+250nM BiRDS, and nucleic acid drug (last day of bleomycin injection, beginning with nucleic acid drug). The drug volumes were 100 μl, miR27a concentration was 750nM, tFNA (T) concentration was 250nM, biRDS concentrations were 125nM and 250nM. Skin tissue (harvested on days 0, 7, 14 and 21, respectively) and viscera (harvested on day 21) were harvested for tissue analysis by injection of 3 weeks of nucleic acid drug (injected every two days over a period of 3 weeks). miR27a is miRNA-27a, T is tFNA, and miRNA-27a, tFNA and BiRDS are as described in example 1.
Skin thickness and histopathological analysis: dehydrated and paraffin-embedded tissues were sectioned into 4 μm sections. The skin was flattened and sectioned longitudinally to observe a lesion in the center of the tissue using an FSX100 microscope (olympus, tokyo, japan). Skin fibrosis was assessed by measuring the vertical epithelial thickness of the blue fibrotic fraction after Masson staining. HE staining was used to observe histological changes of skin and viscera. The dried sections were immediately placed in xylene, dewaxed for 5-10 minutes, and placed in 100% -70% alcohol until the alcohol was washed with water. After staining with hematoxylin and eosin, the tissue was dehydrated. For ease of observation and storage, neutral balsam was dropped on paper towels and baked.
Immunohistochemical analysis: for immunohistochemistry, the remaining sample sections were incubated overnight in diluted primary antibody at 4 ℃, including mouse anti-TGF- β. Specific dilutions of anti-rabbit secondary antibodies (1:600, USA) were used for 20min at 37 ℃. After development, washing, dehydration and mounting, the sections were imaged using an optical microscope.
Distribution of BiRDS and tFNA in vivo: in order to study the distribution, stability and absorption rate of the injected drug, the present invention performed in vivo imaging experiments after in vivo injection of Cy5-BiRDS (250 nM), cy5-tFNA (250 nM, cy5 in S1-3) and Cy5-mi27a (750 nM) in mice. After various time periods (0, 15, 30, 60 and 120 minutes), mice were anesthetized with isoflurane and imaged using an in vivo imaging system (IVIS Spectrum). After 120 minutes, mice were sacrificed to separate organs such as skin, heart, liver, spleen, lung, and kidney that were simultaneously exposed.
2. Experimental results
2.1BiRDS reduced fibers in the epithelium and maintained the epithelial structure
In the last three weeks of treatment, the invention collected skin tissue in the back every 7 days and viscera on day 21 for detection. Skin thickness is often the primary endpoint of bleomycin-induced fibrosis, and can be specifically labeled with Masson trichromatography (fig. 4B). The present invention measured the height from epidermis to subcutaneous tissue in three random non-overlapping pictures of each group, with the average measurement of bleomycin (B) group dermis thickness increasing from 334.2 μm to 394.4 μm over time (fig. 4C). On day 21, the skin thickness was reduced in all treatment groups. BiRDS (125 nM) and tFNA (250 nM) showed the same effect as 750nM miR-27a. The thinnest skin tissue was observed in the 250nM BiRDS group. Experimental results of hydroxyproline evaluation provide further verification of the fibrosis content. Hydroxyproline is formed from the posttranslationally hydroxylated amino acid proline, which is primarily limited to collagen. Fig. 4D shows the hydroxyproline content at the end of the experiment and shows a similar trend to skin thickness. Group B reached 0.64 μg/mg, three times more than the control group, while the 250nM BiRDS reversed its effect to 0.20 μg/mg.
During injection, the experimenter clearly felt that the skin of the mice became more rough and stiff, and HE staining was performed in order to observe the microstructure of the skin tissue (fig. 4E). The solid line box and the dashed line box represent the features and changes of the epithelial and subcutaneous tissues, respectively. In the control group, the present invention observed a large number of dermal papillae, normal glandular structures, abundant subcutaneous adipose tissue and capillaries. However, the severe fibrotic process causes the glandular, fatty and dermal papillae to disappear, with the dilated blood vessels increasingly occupying additional sites in the subcutaneous tissue. Injection of 750nM miR-27a and 125nM BiRDS restored only a portion of the structure, whereas 250nM tRNA and BiRDS showed significant therapeutic effects.
2.2BiRDS maintained the stability of miR-27a and demonstrated skin targeting
To examine metabolism in various organs after subcutaneous injection of drug, the present invention tested the distribution of certain points with IVIS spectroscopy within 120 minutes (fig. 4F). The isosteric drug was injected into bleomycin-induced fibrosis mice. A similar initial strength was ensured immediately after injection. After 15 minutes, the fluorescence intensity of miR-27a drops sharply and remains at a lower level for the last 90 minutes. In contrast, higher concentrations of BiRDS remained in skin tissue and slowly declined to lower levels at 120 minutes, but still higher than bare miR-27a. The degradation of tFNA is relatively uniform compared to the other two drugs, probably because of their lower absorption rate. BiRDS protects the stability of the DNA/RNA single strand and can target organs. The invention showed the lowest fluorescence in the miR-27a group and the strongest fluorescence in the BiRDS-injected skin, indicating its greater stability and higher skin targeting ability (fig. 4G). In addition, weak Cy5 fluorescence was observed in the liver at 120 minutes, indicating that the drug was metabolized in the liver, as previously reported by our group. In our experiments, biRDS showed no significant toxicity in organs and very strong biocompatibility.
2.3BiRDS inhibits the TGF-beta/smad pathway in vivo
During bleomycin-stimulated pathology, latent TGF- β molecules are initiated by a variety of proteases, such as plasmin and metalloproteinases. TGF-. Beta.is also a potent inducer of epithelial cell to myofibroblast cell, characterized by expression of alpha-SMA (FIG. 5A). More and more myofibroblasts express an excess of ECM, while the excess protein is under-decomposed. IHC results indicate that the TGF- β content in the bleomycin group is increased approximately 2.3-fold (FIGS. 5B and 5E). Surprisingly, all treatment groups showed significant therapeutic effects. Naked miR-27a reduced the content to 1.4 times that of the control group, while 250nM BiRDS kept it at a minimum level, almost identical to the control group. tFNA and 250nM BiRDS have excellent curative effect in inhibiting alpha-SMA; the latter group was the most potent, reaching 1.2 times that of the non-fibrotic group (fig. 5C and 5F). BiRDS at 250nM inhibited both fibronectin and Smad proteins (FIGS. 5D and 5G)
2.4BiRDS inhibit Pyropysis-related proteins and TNF-alpha
The in vitro experiment of the invention shows that BiRDS carrying miR-27a inhibits the focal sagging pathway. In order to evaluate the regulation of BiRDS in vivo pathology, immunofluorescence and IHC experiments were performed on cleaved caspase-1 and IL-1β, and semi-quantitative analysis was performed on target proteins. Bleomycin-induced inflammation and fibrosis promoted strong expression of cleaved caspase-1 in hair follicles, sebaceous glands and subcutaneous tissue (fig. 6A and 6D). The expression of the downstream inflammatory cytokine IL-1β varies in the same manner. In contrast to tFNA, each BiRDS particle contains three NLRP 3-targeting miR-27a molecules that mediate the typical focal sagging pathway. Thus, biRDS may inhibit each step of the pyrosis cascade pathway with the highest efficiency in the four groups. IL-1β, the last loop of the pyrosis pathway, is a cytokine secreted by GSDMD pores, which promotes inflammatory responses. The expression level of bleomycin group IL-1β was increased three times and the BiRDS reduced its level slightly above the first group (fig. 6B and 6E). The present invention also detects the expression of tumor necrosis factor alpha (TNF-alpha), which is a key driver of fibrosis. This factor strongly affects the amplification and persistence of tissue damage and fibrosis. BiRDS also inhibited TNF- α expression most effectively at 250nM (FIGS. 6C and 6F), indicating that BiRDS has greater efficacy than tFNA in inhibiting pyrosis and other inflammatory factors, improved anti-pyropic and anti-inflammatory activity, and reduced fibrosis.
In summary, the invention provides a novel tetrahedral nanomaterial, which carries miRNA-27a molecules, and the tetrahedral nanomaterial can resist apoptosis and anti-inflammatory activity, can reduce skin fibrosis, can be used for preparing nucleic acid medicines for treating skin fibrosis, and has wide application prospect.
Claims (10)
1. A tetrahedral framework nanomaterial for treating skin fibrosis, characterized in that: it is obtained by base complementary pairing of nucleotide sequences shown in SEQ ID NO. 5-8.
2. The tetrahedral framework nanomaterial of claim 1, wherein: the mol ratio of the nucleotide sequence shown in SEQ ID NO. 5-7 to the nucleotide sequence shown in SEQ ID NO.8 is (1-5): 1-5: 3-15.
3. The tetrahedral framework nanomaterial of claim 2, wherein: the molar ratio of the nucleotide sequence shown in SEQ ID NO. 5-7 to the nucleotide sequence shown in SEQ ID NO.8 is 1:1:1:3.
4. A method for preparing a tetrahedral framework nanomaterial according to any of claims 1 to 3, characterized in that: it comprises the following steps:
mixing the nucleotide sequences shown in SEQ ID No. 5-8 in a solvent, maintaining the temperature at 90-95 ℃ for 10-20 minutes, and rapidly cooling to 4-10 ℃ and maintaining the temperature for more than 20 minutes to obtain the nucleotide sequence.
5. The method of manufacturing according to claim 4, wherein: the solvent is a TM buffer.
6. The method of manufacturing according to claim 5, wherein: the TM buffer is prepared from 10mM Tris-HCl and 50mM MgCl 2 Dissolving in water, and adjusting pH to 8.0.
7. Use of a tetrahedral framework nanomaterial according to any of claims 1 to 3 for the preparation of a nucleic acid drug for the treatment of skin fibrosis.
8. Use according to claim 7, characterized in that: the nucleic acid medicine is an anti-cell apoptosis medicine.
9. Use according to claim 7, characterized in that: the nucleic acid drug is an anti-inflammatory drug.
10. Use according to claim 7, characterized in that: the nucleic acid drug is a drug for inhibiting TGF-beta/Smad channels.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311158848.2A CN116983320A (en) | 2023-09-08 | 2023-09-08 | Nucleic acid medicine for treating skin fibrosis and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311158848.2A CN116983320A (en) | 2023-09-08 | 2023-09-08 | Nucleic acid medicine for treating skin fibrosis and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116983320A true CN116983320A (en) | 2023-11-03 |
Family
ID=88521549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311158848.2A Pending CN116983320A (en) | 2023-09-08 | 2023-09-08 | Nucleic acid medicine for treating skin fibrosis and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116983320A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116139285A (en) * | 2022-07-07 | 2023-05-23 | 四川大学 | Biological switchable miR nano-composite based on DNA tetrahedral framework nucleic acid and preparation method and application thereof |
-
2023
- 2023-09-08 CN CN202311158848.2A patent/CN116983320A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116139285A (en) * | 2022-07-07 | 2023-05-23 | 四川大学 | Biological switchable miR nano-composite based on DNA tetrahedral framework nucleic acid and preparation method and application thereof |
CN116139285B (en) * | 2022-07-07 | 2024-05-31 | 四川大学 | Biological switchable miR nano-composite based on DNA tetrahedral framework nucleic acid and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7372619B2 (en) | Method of treatment | |
US20190133922A1 (en) | Stem Cell-Derived Exosomes Containing a High Amount of Growth Factors | |
KR101397912B1 (en) | Visfatin therapeutic agents for the treatment of acne and other conditions | |
KR102012527B1 (en) | Novel activator peptides for synthesizing extracellular matrix proteins, and cosmetic compositions including same | |
JP2011504170A (en) | Multi-targeted RNAi therapeutics for scarless injury healing in the skin | |
KR101830926B1 (en) | Use of pedf-derived polypeptides for preventing and/or ameliorating skin aging | |
JPH0611709B2 (en) | Composition for the treatment of corneal matrix wounds | |
Dong et al. | IL-27 attenuates the TGF-β1-induced proliferation, differentiation and collagen synthesis in lung fibroblasts | |
CN116983320A (en) | Nucleic acid medicine for treating skin fibrosis and preparation method and application thereof | |
JP6416240B2 (en) | Tetrapeptide derived from human C—X—C chemokine useful for treatment of various skin conditions | |
CN110123838A (en) | Load human pluripotent stem cells excretion body of resveratrol and preparation method thereof and purposes | |
Mathison et al. | Cardiac reprogramming factor Gata4 reduces postinfarct cardiac fibrosis through direct repression of the profibrotic mediator snail | |
KR20160134738A (en) | Aptamers for topical delivery | |
CN111467477A (en) | Topical compositions comprising a P L I-OB variant | |
CN110403907A (en) | It the purposes of compound stem cell regenerating peptide suspension and its prepares | |
CN114569628A (en) | Use of DNA tetrahedral framework nano-nucleic acid in cosmetology | |
CN110903348B (en) | Small peptide for promoting wound healing and application thereof | |
Bo et al. | Exosomes derived from miR-16-5p-overexpressing keratinocytes attenuates bleomycin-induced skin fibrosis | |
CN105120884A (en) | Short bio-active peptides for promoting wound healing | |
WO2024125641A1 (en) | Series of polypeptides/proteins and uses thereof | |
KR102043248B1 (en) | Lipid nano particle complex comprising aptide fused with cell penentrating materials and use same | |
CN116688131A (en) | Inhibitor and application thereof in preparation of products for treating inflammatory skin diseases | |
US20230406897A1 (en) | Method for isolating and culturing cord blood stem cells expressing gdf-3 at high level, and use of gdf-3 | |
US20200376138A1 (en) | Lipid nano particle complex comprising aptide fused with cell penetrating materials and use same | |
US20230241121A1 (en) | Compositions and methods relating to exosomes derived from human dermal papilla cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |